BridgeBio Pharma, Inc. Proceeds from Convertible Debt
BridgeBio Pharma, Inc. (BBIO) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2024-02-22
- BridgeBio Pharma, Inc. proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- BridgeBio Pharma, Inc. proceeds from convertible debt for the quarter ending 2021-09-30 was $0.00.
- BridgeBio Pharma, Inc. proceeds from convertible debt for the quarter ending 2021-06-30 was $0.00.
- BridgeBio Pharma, Inc. proceeds from convertible debt for the quarter ending 2021-03-31 was $747.50M, a 35.91% increase year-over-year.
- BridgeBio Pharma, Inc. proceeds from convertible debt for fiscal 2023 was $0.00.
- BridgeBio Pharma, Inc. proceeds from convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BridgeBio Pharma, Inc. proceeds from convertible debt for fiscal 2021 was $747.50M, a 35.91% increase from fiscal 2020.
- BridgeBio Pharma, Inc. proceeds from convertible debt for fiscal 2020 was $550.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $747.50M 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $747.50M 10-Q · filed 2022-11-03 | $747.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $747.50M 10-Q · filed 2022-08-04 | $747.50M derived: sum of 3 quarters · filed 2023-02-23 | $747.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $747.50M 10-Q · filed 2022-05-05 | $747.50M derived: sum of 2 quarters · filed 2023-02-23 | $747.50M derived: sum of 3 quarters · filed 2023-02-23 | $747.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $550.00M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $550.00M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $550.00M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $550.00M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |